We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Global Blood Focuses on Lead Candidate Amid Competition
Read MoreHide Full Article
We issued an updated report on Global Blood Therapeutics, Inc. on Sep 2.
The company’s lead product candidate is voxelotor (GBT440), an oral, once-daily treatment for sickle cell disease (SCD). SCD is a chronic, inherited blood disorder that affects hemoglobin. The company is evaluating voxelotor in a phase III HOPE study in adult and adolescent patients with SCD. Data from the study, presented in December 2018, demonstrated rapid, robust and sustained improvements in hemoglobin levels and measures of hemolysis, with a favorable safety and tolerability profile for both 1500 mg and 900 mg doses.
In the second quarter of 2019, the company announced a final agreement with the FDA on the design of the post-approval confirmatory study of voxelotor to demonstrate stroke risk reduction benefit of the drug, considering transcranial doppler (TCD) flow velocity as the primary endpoint.
Shares of the company have gained 12% year to date against the industry’s decline of 1.7%.
The FDA approved a rolling submission of voxelotor for the potential treatment of SCD. The company expects to submit an NDA in the second half of 2019.
In August 2018, the company entered an exclusive worldwide license agreement with drug giant Roche Holding AG (RHHBY - Free Report) for the development and commercialization of inclacumab, a novel, fully human monoclonal antibody against P-selectin, as a treatment for vaso-occlusive crises (“VOC”) in patients with SCD.
However, Global Blood has no approved products in its portfolio yet. The company has only one candidate, voxelotor, which is in late-stage studies. If the company is unable to receive regulatory approval for the drug, its business will be significantly affected, as inclacumab is in early stages of development.
The company is also battling stiff competition. The FDA has accepted Novartis’ (NVS - Free Report) Biologics License Application (BLA) for its investigational sickle cell medicine, crizanlizumab (SEG101), and granted Priority Review to the same. Pfizer (PFE - Free Report) is also developing rivipansel for the treatment of VOC in patients with SCD.
Legalizing THIS Could Be Even Bigger than Marijuana
Americans spend an estimated $150 billion in this industry every year… more than twice as much as they spend on marijuana.
Now that 8 states have fully-legalized it (with several more states following close behind), Zacks has identified 5 stocks that could soar in response to the powerful demand. One industry insider described the future as “mind-blowing” – and early investors can still get in ahead of the surge.
Image: Bigstock
Global Blood Focuses on Lead Candidate Amid Competition
We issued an updated report on Global Blood Therapeutics, Inc. on Sep 2.
The company’s lead product candidate is voxelotor (GBT440), an oral, once-daily treatment for sickle cell disease (SCD). SCD is a chronic, inherited blood disorder that affects hemoglobin. The company is evaluating voxelotor in a phase III HOPE study in adult and adolescent patients with SCD. Data from the study, presented in December 2018, demonstrated rapid, robust and sustained improvements in hemoglobin levels and measures of hemolysis, with a favorable safety and tolerability profile for both 1500 mg and 900 mg doses.
In the second quarter of 2019, the company announced a final agreement with the FDA on the design of the post-approval confirmatory study of voxelotor to demonstrate stroke risk reduction benefit of the drug, considering transcranial doppler (TCD) flow velocity as the primary endpoint.
Shares of the company have gained 12% year to date against the industry’s decline of 1.7%.
The FDA approved a rolling submission of voxelotor for the potential treatment of SCD. The company expects to submit an NDA in the second half of 2019.
In August 2018, the company entered an exclusive worldwide license agreement with drug giant Roche Holding AG (RHHBY - Free Report) for the development and commercialization of inclacumab, a novel, fully human monoclonal antibody against P-selectin, as a treatment for vaso-occlusive crises (“VOC”) in patients with SCD.
However, Global Blood has no approved products in its portfolio yet. The company has only one candidate, voxelotor, which is in late-stage studies. If the company is unable to receive regulatory approval for the drug, its business will be significantly affected, as inclacumab is in early stages of development.
The company is also battling stiff competition. The FDA has accepted Novartis’ (NVS - Free Report) Biologics License Application (BLA) for its investigational sickle cell medicine, crizanlizumab (SEG101), and granted Priority Review to the same. Pfizer (PFE - Free Report) is also developing rivipansel for the treatment of VOC in patients with SCD.
Global Blood currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legalizing THIS Could Be Even Bigger than Marijuana
Americans spend an estimated $150 billion in this industry every year… more than twice as much as they spend on marijuana.
Now that 8 states have fully-legalized it (with several more states following close behind), Zacks has identified 5 stocks that could soar in response to the powerful demand. One industry insider described the future as “mind-blowing” – and early investors can still get in ahead of the surge.
See these 5 “sin stocks” now >>